Delcath Systems, Inc. has published new subgroup analyses from its Phase 3 FOCUS trial of HEPZATO KIT—a liver-directed therapy combining melphalan with the proprietary Hepatic Delivery System—for patients with unresectable metastatic uveal melanoma (mUM). The data, now available in the Journal of Cancer Research and Clinical Oncology, suggest that early intervention in patients with low tumor burden may significantly improve survival outcomes, reinforcing the clinical positioning of HEPZATO as the only FDA-approved liver-directed option for this ultra-rare melanoma subtype.

What the subgroup data reveals about treatment timing and tumor burden

The key clinical implication emerging from the published subgroup analysis is that patients with lower hepatic tumor burden and normal LDH levels experience materially better survival outcomes than their higher-burden counterparts. Specifically, median overall survival (OS) rose to 26.7 months for patients with below-median tumor burden, compared to just 15.4 months in the higher-burden group. Similarly, patients with low/normal LDH saw median OS extend to 23.4 months versus 15.3 months in those with elevated levels.

While earlier results from the FOCUS study established the efficacy of HEPZATO KIT in mUM broadly, the new subgroup analysis brings sharper clarity to which patients benefit most and when intervention should occur. This has implications for referral timing, eligibility thresholds, and perhaps the future design of label-expanding trials. The data also appear to validate clinical heuristics long used by interventional oncologists treating hepatic metastases: early loco-regional intervention before liver burden exceeds 50% improves systemic outcomes.

Why consistency across subgroups strengthens confidence

A key message from the analysis is the consistency of tumor response and safety outcomes across diverse clinical subgroups. Regardless of age, sex, geographic region, prior therapy, or presence of extrahepatic disease, the efficacy of HEPZATO remained broadly stable, suggesting the platform is both flexible and reliable in real-world settings.

Objective response rates (ORR) were significantly higher in patients with lower tumor burden (51.1% vs. 22.2%), while progression-free survival (PFS) doubled (11.3 vs. 5.8 months). Importantly, no new safety signals emerged even with repeated administration across six cycles. The absence of cumulative toxicity is particularly relevant in a disease where options are few, and treatment durability is critical.

This stability across heterogeneous patient cohorts strengthens the argument for HEPZATO’s scalability across broader real-world populations, potentially reducing clinician hesitation in initiating liver-directed therapy in less conventional cases.

What HEPZATO offers that systemic immunotherapies cannot

HEPZATO’s regulatory positioning as a drug-device combination delivering high-dose melphalan via percutaneous hepatic perfusion (PHP) makes it unique. Unlike immune checkpoint inhibitors or targeted therapies that circulate systemically, HEPZATO isolates hepatic venous blood, filters it, and limits systemic exposure. This allows a much higher chemotherapeutic dose to be delivered directly to the liver, a crucial advantage given that liver metastases drive mortality in most mUM patients.

This liver-centric approach also provides an alternative for patients who are either unresponsive or ineligible for immunotherapy, particularly since uveal melanoma is known for its immune-cold phenotype and poor response rates to PD-1/L1 blockade. As such, HEPZATO fills a critical mechanistic and clinical gap in the current treatment landscape for mUM.

How regulatory precedent in the United States differs from Europe

HEPZATO KIT received U.S. FDA approval as a combination product for adult patients with unresectable mUM involving less than 50% of the liver and limited extrahepatic disease. The European pathway diverged, with the CHEMOSAT configuration of the hepatic delivery device approved separately as a Class III medical device under EU regulation. This has allowed the platform to be used more broadly in percutaneous hepatic perfusion procedures across a range of hepatic tumors in major EU centers.

While this difference in regulatory framing has slowed harmonization of clinical strategies, the new U.S. subgroup data may help prompt realignment of global practice patterns, particularly in markets considering label expansion or post-approval observational registries.

Why clinicians may reevaluate cycle duration and response monitoring

An underappreciated insight from the new subgroup report is the timing of observed responses. Of the 33 patients who achieved an objective response, 57.6% responded within the first or second cycle. However, a full one-third of responses (33.3%) emerged only in cycles four through six. This has implications for both clinical decision-making and health system reimbursement, as it reinforces the rationale for completing the full six-cycle regimen before determining futility or switching to systemic alternatives.

From a clinical operations perspective, this may encourage longer persistence with HEPZATO therapy in borderline responders, especially in patients whose tumor burden is still within the optimized range. Given the historical tendency to move rapidly through treatment lines in rare cancers, this could reset expectations around time-to-response in liver-directed chemoperfusion.

What risks and unknowns still limit broader use

Despite its promise, HEPZATO’s future expansion is not without constraints. First, its indication is limited to patients with hepatic metastases comprising less than 50% of liver volume, excluding many patients at first presentation. Second, the presence of certain types of extrahepatic disease remains a barrier, and the long-term impact of retreatment beyond six cycles is unclear.

There is also a potential infrastructure challenge: HEPZATO delivery requires catheterization expertise, filtration equipment, and coordination across oncology, surgery, and interventional radiology—making it harder to deploy outside of major academic centers or specialty networks.

From a commercial standpoint, market penetration may also hinge on payer receptiveness to high-cost interventional therapies and real-world survival data across community settings. Nonetheless, the consistent subgroup efficacy profile may strengthen value-based arguments as more outcome data becomes available.

What could come next in Delcath’s strategic roadmap

Industry observers are watching whether Delcath Systems will now pursue label expansions beyond mUM, especially given the European CHEMOSAT footprint in broader hepatic tumor types such as colorectal liver metastases or hepatocellular carcinoma. Subgroup data of this granularity helps bolster Delcath’s credibility as a precision interventional oncology player, and may aid both global reimbursement discussions and trial design for new indications.

There may also be movement toward adjuvant or neoadjuvant applications, especially if HEPZATO’s liver-directed approach can be shown to downstage disease ahead of resection or consolidate remission after systemic therapy. The rising visibility of interventional oncology as a therapeutic discipline—not just a procedural one—gives HEPZATO strategic momentum at a time when liver metastasis management is becoming increasingly multimodal.

  Delcath Systems, FOCUS study, HEPZATO KIT, interventional oncology, liver-directed therapy, melphalan, metastatic uveal melanoma, oncology devices, subgroup analysis